Statistics

Total Visits

Views
Switching to dual therapy (atazanavir/ritonavir+lamivudine) vs. standard triple therapy (atazanavir/ritonavir+2 nucleos[t]ides) is safe and effective in virologically suppressed patients: 48-week results of a randomized clinical trial (SALT study)42

Select a period of time:

Number of views in the range

Views
Switching to dual therapy (atazanavir/ritonavir+lamivudine) vs. standard triple therapy (atazanavir/ritonavir+2 nucleos[t]ides) is safe and effective in virologically suppressed patients: 48-week results of a randomized clinical trial (SALT study)4

Views

Views
October 20250
November 20250
December 20252
January 20260
February 20262
March 20260
April 20260
Download CSV file
 untranslated
 untranslated

Top country views

Views
Argentina1
United Kingdom1
Malta1
United States1
 

Top cities views

Views
Ashburn1
Buenos Aires1
Victoria1